1. Beyond stating that the drug was generally well tolerated in all three arms, the Company said there was no impairment of oxygen delivery in the setting of drug exposures that were approximately twice the highest levels that will be achieved in sickle-cell disease patients (were referring to the 1500mg arm which was highest dose tested in this trial and also highest dose being tested in ongoing P3 SCD trial).
2. Drug exposure in IPF patients is about double that of SCD patients due to the instability of red blood cells in SCD patients. GBT440 is cleared more rapidly in SCD patients because red blood cells are being destroyed by the polymerization process. This does not happen in IPF patients. Drug half-life is 1.5 days in SCD patients and about 3 days in non-SCD patients.
Market Data 
Markets 
AI
